Share on StockTwits

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Director Erich Sager unloaded 10,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $11.01, for a total value of $110,100.00. Following the transaction, the director now directly owns 74,297 shares in the company, valued at approximately $818,010. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded down 2.09% during mid-day trading on Wednesday, hitting $11.22. The stock had a trading volume of 1,084,866 shares. Raptor Pharmaceutical Corp. has a 1-year low of $7.12 and a 1-year high of $17.72. The stock has a 50-day moving average of $9.76 and a 200-day moving average of $10.5. The company’s market cap is $704.0 million. Raptor Pharmaceutical Corp. also saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 15,901,536 shares, a growth of 7.3% from the July 31st total of 14,819,552 shares. Based on an average daily volume of 929,597 shares, the days-to-cover ratio is currently 17.1 days. Approximately 27.3% of the company’s stock are short sold.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. The company had revenue of $16.31 million for the quarter, compared to the consensus estimate of $14.58 million. The company’s revenue for the quarter was up 77566.7% on a year-over-year basis. On average, analysts predict that Raptor Pharmaceutical Corp. will post $-0.74 earnings per share for the current fiscal year.

Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.

Receive News & Ratings for Raptor Pharmaceutical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.